



# DURECT to Present at the Jefferies Healthcare Conference

CUPERTINO, Calif., June 3, 2011 /PRNewswire via COMTEX/ —

DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and CEO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 7 at 4:30 p.m. Eastern time. The conference is being held at the Grand Hyatt in New York .

(Logo: <http://photos.prnewswire.com/prnh/20020717/DRRXLOGO>)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at [www.durect.com](http://www.durect.com) and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXYÂ®, POSIDUR(TM), ELADURÂ®, and TRANSDURÂ®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit [www.durect.com](http://www.durect.com).

NOTE: POSIDUR(TM), SABER(TM), ORADURÂ®, TRANSDURÂ®, and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation